{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:59:32Z","timestamp":1777953572072,"version":"3.51.4"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Health and Medical Research Council (NHMRC) Centre of Research Excellence in Medicines Intelligence","award":["1196900"],"award-info":[{"award-number":["1196900"]}]},{"name":"UNSW Research Infrastructure Scheme"},{"name":"Cancer Institute New South Wales Early Career Fellowship","award":["ECF1381"],"award-info":[{"award-number":["ECF1381"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Polypharmacy is associated with increased risks of adverse outcomes in people with cancer and medicine use evolves over the course of the disease trajectory. We estimated the prevalence of polypharmacy in people with colorectal cancer (CRC), stratified by extent of disease spread at diagnosis, during each year from 1 year prior to 5 years following diagnosis and determined factors associated with polypharmacy at diagnosis and 2- and 5-year postdiagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>Our retrospective cohort study used linked administrative health records from New South Wales (NSW), Australia to examine medicine use in all NSW residents \u226518\u2009years diagnosed with CRC between 2013 and 2017. We defined polypharmacy as concomitant exposure to \u22655 medicines, excluding antineoplastics, during at least one 90-day quarter in each year from diagnosis. We used logistic regression to examine associations between polypharmacy and relevant factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 19\u00a0056 people diagnosed with CRC, 6797 (35%), 8482 (45%), and 3777 (20%) were diagnosed with localized, regional, and metastatic disease, respectively. Within these groups, 74%-79% experienced polypharmacy at any time during the study period; with nearly 50% experiencing polypharmacy 2 through 5 years from diagnosis. Age (\u226570\u2009years), female sex, comorbidities, colon cancer diagnosis, and socioeconomic disadvantage were associated with increased likelihood of polypharmacy at all landmarks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Polypharmacy is highly prevalent among Australians with CRC. For those treated with curative intent, higher polypharmacy rates are concerning, indicating excess morbidity and impaired quality of life among survivors cured of cancer but who may continue to experience poorer health than the general population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf380","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T12:33:29Z","timestamp":1765197209000},"source":"Crossref","is-referenced-by-count":0,"title":["Polypharmacy among people diagnosed with colorectal cancer in Australia: a population-based cohort study"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8617-6055","authenticated-orcid":false,"given":"Benjamin","family":"Daniels","sequence":"first","affiliation":[{"name":"Medicines Intelligence Research Program, School of Population Health, UNSW Sydney , Sydney, NSW 2052,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Tang","sequence":"additional","affiliation":[{"name":"Medicines Intelligence Research Program, School of Population Health, UNSW Sydney , Sydney, NSW 2052,","place":["Australia"]},{"name":"Nelune Comprehensive Cancer Centre, Prince of Wales Hospital , Sydney, NSW 2052,","place":["Australia"]},{"name":"School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney , Sydney, NSW 2052,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Aslam","sequence":"additional","affiliation":[{"name":"Maitland Hospital, Hunter New England Local Health District , NSW 2323,","place":["Australia"]},{"name":"Hunter Medical Research Institute, University of Newcastle , NSW 2305,","place":["Australia"]},{"name":"School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle , Newcastle, NSW 2308,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7137-6855","authenticated-orcid":false,"given":"Sallie-Anne","family":"Pearson","sequence":"additional","affiliation":[{"name":"Medicines Intelligence Research Program, School of Population Health, UNSW Sydney , Sydney, NSW 2052,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"2026050411585504300_oyaf380-B1"},{"key":"2026050411585504300_oyaf380-B2","volume-title":"Bowel cancer (colorectal cancer) in Australia statistics Canberra","author":"Cancer Australia","year":"2025"},{"key":"2026050411585504300_oyaf380-B3","first-page":"233","article-title":"Colorectal cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"2026050411585504300_oyaf380-B4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(24)00600-4","article-title":"Colorectal cancer incidence trends in younger versus older adults: an analysis of population-based cancer registry data","volume":"26","author":"Sung","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026050411585504300_oyaf380-B5","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","article-title":"What is polypharmacy? A systematic review of definitions","volume":"17","author":"Masnoon","year":"2017","journal-title":"BMC Geriatr"},{"key":"2026050411585504300_oyaf380-B6","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.jgo.2019.01.012","article-title":"Potentially inappropriate medication use and associated healthcare utilization and costs among older adults with colorectal, breast, and prostate cancers","volume":"10","author":"Feng","year":"2019","journal-title":"J Geriatr Oncol"},{"key":"2026050411585504300_oyaf380-B7","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1002\/cncr.31403","article-title":"Potentially inappropriate medication use in older patients with breast and colorectal cancer","volume":"124","author":"Karuturi","year":"2018","journal-title":"Cancer"},{"key":"2026050411585504300_oyaf380-B8","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1634\/theoncologist.2019-0406","article-title":"Associations of polypharmacy and inappropriate medications with adverse outcomes in older adults with cancer: a systematic review and meta-analysis","volume":"25","author":"Mohamed","year":"2020","journal-title":"Oncologist"},{"key":"2026050411585504300_oyaf380-B9","doi-asserted-by":"crossref","first-page":"e2170","DOI":"10.1002\/onco.13961","article-title":"Association of polypharmacy with colorectal cancer survival among older patients","volume":"26","author":"Chen","year":"2021","journal-title":"Oncologist"},{"key":"2026050411585504300_oyaf380-B10","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1002\/cncr.34813","article-title":"Association of polypharmacy with all-cause mortality and adverse events among elderly colorectal cancer survivors","volume":"129","author":"Choi","year":"2023","journal-title":"Cancer"},{"key":"2026050411585504300_oyaf380-B11","doi-asserted-by":"crossref","first-page":"e5887","DOI":"10.1002\/pds.5887","article-title":"The medicines intelligence data platform: a population-based data resource from New South Wales","volume":"33","author":"Zoega","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026050411585504300_oyaf380-B12","volume-title":"National, State and Territory Population","author":"Australian Bureau of Statistics","year":"2020"},{"key":"2026050411585504300_oyaf380-B13","volume-title":"Centre for Health Record Linkage New South Wales","author":"Centre for Health Record Linkage","year":"2025"},{"key":"2026050411585504300_oyaf380-B14","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1186\/s13104-015-1616-8","article-title":"The Australian pharmaceutical benefits scheme data collection: a practical guide for researchers","volume":"8","author":"Mellish","year":"2015","journal-title":"BMC Res Notes"},{"key":"2026050411585504300_oyaf380-B15","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1002\/pds.5093","article-title":"A national study on prescribed medicine use in Australia on a typical day","volume":"29","author":"Wylie","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026050411585504300_oyaf380-B16","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1111\/bcp.14504","article-title":"Long-term trajectories of medicine use among older adults experiencing polypharmacy in Australia","volume":"87","author":"Falster","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2026050411585504300_oyaf380-B17","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1002\/sim.7019","article-title":"Use of the landmark method to address immortal person-time bias in comparative effectiveness research: a simulation study","volume":"35","author":"Mi","year":"2016","journal-title":"Stat Med"},{"key":"2026050411585504300_oyaf380-B18","volume-title":"Australian Statistical Geography Standard (ASGS): Volume 5\u2014Remoteness Structure, July 2016","author":"Australia Bureau of Statistics","year":"2018"},{"key":"2026050411585504300_oyaf380-B19","volume-title":"Census of Population and Housing: Socio-Economic Indexes for Areas (SEIFA), Australia, 2016","author":"Australia Bureau of Statistics","year":"2018"},{"key":"2026050411585504300_oyaf380-B20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5694\/mja2.50244","article-title":"Polypharmacy among older Australians, 2006\u20132017: a population-based study","volume":"211","author":"Page","year":"2019","journal-title":"Med J Aust"},{"key":"2026050411585504300_oyaf380-B21","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1002\/cncr.31389","article-title":"Polypharmacy and patterns of prescription medication use among cancer survivors","volume":"124","author":"Murphy","year":"2018","journal-title":"Cancer"},{"key":"2026050411585504300_oyaf380-B22","first-page":"1727","article-title":"Prevalence and factors associated with polypharmacy in older people with cancer","volume":"22","author":"Turner","year":"2014","journal-title":"Support Care Cancer"},{"key":"2026050411585504300_oyaf380-B23","doi-asserted-by":"crossref","first-page":"e502","DOI":"10.1634\/theoncologist.2019-0085","article-title":"Polypharmacy, inappropriate medication use, and drug interactions in older Korean patients with cancer receiving first-line palliative chemotherapy","volume":"25","author":"Hong","year":"2020","journal-title":"Oncologist"},{"key":"2026050411585504300_oyaf380-B24","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1007\/s11136-022-03136-9","article-title":"Polypharmacy and trajectories of health-related quality of life in older adults: an Australian cohort study","volume":"31","author":"Aljeaidi","year":"2022","journal-title":"Qual Life Res"},{"key":"2026050411585504300_oyaf380-B25","doi-asserted-by":"crossref","first-page":"E50","DOI":"10.5888\/pcd19.220062","article-title":"Polypharmacy and health-related quality of life\/psychological distress among patients with chronic disease","volume":"19","author":"Van Wilder","year":"2022","journal-title":"Prev Chronic Dis."},{"key":"2026050411585504300_oyaf380-B26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11764-019-00837-y","article-title":"Association between polypharmacy and health-related quality of life among cancer survivors in the United States","volume":"14","author":"Babcock","year":"2020","journal-title":"J Cancer Surviv"},{"key":"2026050411585504300_oyaf380-B27","first-page":"100872","article-title":"Prevalence of Australians exposed to potentially cardiotoxic cancer medicines: a population-based cohort study","volume":"39","author":"Daniels","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"2026050411585504300_oyaf380-B28","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1007\/s11136-020-02478-6","article-title":"Psychotropic polypharmacy and its association with health-related quality of life among cancer survivors in the USA: a population-level analysis","volume":"29","author":"Vyas","year":"2020","journal-title":"Qual Life Res"},{"key":"2026050411585504300_oyaf380-B29","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S1470-2045(13)70244-4","article-title":"Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: a systematic review and meta-analysis","volume":"14","author":"Mitchell","year":"2013","journal-title":"Lancet Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf380\/65823712\/oyaf380.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/5\/oyaf380\/65823712\/oyaf380.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/5\/oyaf380\/65823712\/oyaf380.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:59:05Z","timestamp":1777910345000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf380\/8375713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4,10]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf380","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2025,12,9]]},"article-number":"oyaf380"}}